Glycosaminoglycans as Novel Target in Antitumor Therapy

  • JENEY Andras
    I. Institute of Pathology and Experimental Cancer Research, Semmelweis Medical University
  • TIMAR Jozsef
    I. Institute of Pathology and Experimental Cancer Research, Semmelweis Medical University
  • POGANY Gabor
    I. Institute of Pathology and Experimental Cancer Research, Semmelweis Medical University
  • PAKU Sandor
    I. Institute of Pathology and Experimental Cancer Research, Semmelweis Medical University
  • MOCZAR Elemer
    Laboratoire du Tissu Conjonctif, Faculte de Medecine
  • MAREEL Mark
    Laboratory of Experimental Cancerology, Department of Radiotherapy, and Nuclear Medicine, Academic Hospital
  • OTVOS Laszlo
    Central Research Institute of Chemistry, Hungarian Academy of Sciences
  • KOPPER Laszlo
    I. Institute of Pathology and Experimental Cancer Research, Semmelweis Medical University
  • LAPIS Karoly
    I. Institute of Pathology and Experimental Cancer Research, Semmelweis Medical University

この論文をさがす

抄録

Considering the importance of intercellular contacts in the metastasis of malignant tumours drug action on glycosaminoglycan production as one of the underlying mechanisms in metastasis was investigated. 5-hexy1-2-deoxyuridine /HUdR/ was shown to inhibit the conversion of glucosamine to UDP-sugars. Consequently various glycoconjugates were affected, especially the synthesis of heparan sulfate was reduced. It is noteworthy that HUdR inhibited the synthesis of glycosaminoglycans in tumour cells with high metastatic capacity. The biological consequence of the alterations in glycosaminoglycan production was studied on measuring HUdR action on cell surface markers, microinvasion and tumour metastasis in experimental systems. It was concluded that HUdR has remarkable antimetastatic activity which by all probability is due to the inhibition of heparane sulfate synthesis.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ